Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Neoplasms | 41 | 2025 | 22371 | 1.870 |
Why?
|
Immunotherapy | 27 | 2025 | 4754 | 1.650 |
Why?
|
Medical Oncology | 10 | 2024 | 2346 | 1.050 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 33 | 2025 | 11878 | 1.010 |
Why?
|
Melanoma | 14 | 2024 | 5706 | 0.890 |
Why?
|
Clinical Trials as Topic | 13 | 2024 | 8052 | 0.840 |
Why?
|
Mesothelioma | 6 | 2024 | 811 | 0.710 |
Why?
|
Biliary Tract Neoplasms | 3 | 2022 | 187 | 0.690 |
Why?
|
GPI-Linked Proteins | 6 | 2024 | 472 | 0.630 |
Why?
|
Drug Discovery | 3 | 2017 | 1068 | 0.600 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 8 | 2024 | 5432 | 0.580 |
Why?
|
Antibodies, Monoclonal | 12 | 2024 | 9262 | 0.540 |
Why?
|
Biological Therapy | 1 | 2018 | 140 | 0.540 |
Why?
|
National Cancer Institute (U.S.) | 4 | 2023 | 300 | 0.530 |
Why?
|
Antibodies, Bispecific | 4 | 2024 | 204 | 0.530 |
Why?
|
Interleukin-18 | 1 | 2018 | 251 | 0.520 |
Why?
|
Eye Diseases | 1 | 2021 | 660 | 0.500 |
Why?
|
Hepatitis, Autoimmune | 1 | 2018 | 173 | 0.500 |
Why?
|
Skin Neoplasms | 8 | 2024 | 5863 | 0.490 |
Why?
|
Drugs, Investigational | 1 | 2017 | 211 | 0.480 |
Why?
|
Carcinoma, Merkel Cell | 4 | 2021 | 329 | 0.460 |
Why?
|
Myocarditis | 1 | 2022 | 802 | 0.460 |
Why?
|
Autoimmunity | 2 | 2019 | 1361 | 0.450 |
Why?
|
Lung Neoplasms | 11 | 2024 | 13586 | 0.450 |
Why?
|
Pleural Neoplasms | 3 | 2024 | 612 | 0.410 |
Why?
|
Petunia | 2 | 2023 | 3 | 0.410 |
Why?
|
Carcinoma, Hepatocellular | 3 | 2023 | 2334 | 0.410 |
Why?
|
Humans | 118 | 2025 | 768171 | 0.400 |
Why?
|
Research Design | 3 | 2023 | 6209 | 0.400 |
Why?
|
Rare Diseases | 3 | 2024 | 631 | 0.390 |
Why?
|
Disease Susceptibility | 1 | 2018 | 1793 | 0.380 |
Why?
|
Antineoplastic Agents | 9 | 2024 | 13677 | 0.380 |
Why?
|
Developing Countries | 1 | 2024 | 2910 | 0.380 |
Why?
|
Asbestos | 1 | 2013 | 251 | 0.370 |
Why?
|
Iodine Radioisotopes | 1 | 2014 | 1034 | 0.360 |
Why?
|
Receptor, IGF Type 1 | 1 | 2013 | 384 | 0.360 |
Why?
|
Adenoma, Pleomorphic | 1 | 2010 | 77 | 0.330 |
Why?
|
Liver Neoplasms | 3 | 2023 | 4363 | 0.330 |
Why?
|
Carcinoma, Papillary | 1 | 2014 | 793 | 0.320 |
Why?
|
Thyroidectomy | 1 | 2014 | 913 | 0.310 |
Why?
|
Hodgkin Disease | 3 | 2023 | 1384 | 0.310 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 3 | 2023 | 1560 | 0.310 |
Why?
|
Patient Selection | 1 | 2020 | 4260 | 0.310 |
Why?
|
Extracellular Matrix Proteins | 1 | 2013 | 835 | 0.310 |
Why?
|
Adverse Drug Reaction Reporting Systems | 3 | 2024 | 496 | 0.300 |
Why?
|
Neoplasm Staging | 12 | 2025 | 11244 | 0.290 |
Why?
|
Molecular Targeted Therapy | 4 | 2021 | 2830 | 0.280 |
Why?
|
HIV Infections | 6 | 2024 | 17569 | 0.280 |
Why?
|
Combined Modality Therapy | 8 | 2022 | 8542 | 0.270 |
Why?
|
Carcinoma, Transitional Cell | 2 | 2024 | 794 | 0.270 |
Why?
|
Salvage Therapy | 2 | 2025 | 1273 | 0.260 |
Why?
|
Anilides | 3 | 2024 | 413 | 0.260 |
Why?
|
Salivary Gland Neoplasms | 1 | 2010 | 306 | 0.260 |
Why?
|
Lupus Erythematosus, Systemic | 1 | 2018 | 2171 | 0.260 |
Why?
|
Aged | 45 | 2025 | 171502 | 0.260 |
Why?
|
Tuberculosis | 1 | 2019 | 2029 | 0.250 |
Why?
|
Middle Aged | 49 | 2025 | 223487 | 0.250 |
Why?
|
Pandemics | 3 | 2024 | 8747 | 0.250 |
Why?
|
Flowers | 2 | 2023 | 30 | 0.240 |
Why?
|
Trinidad and Tobago | 1 | 2024 | 13 | 0.240 |
Why?
|
Interleukin-7 | 1 | 2025 | 146 | 0.230 |
Why?
|
Aged, 80 and over | 26 | 2025 | 59626 | 0.230 |
Why?
|
Neuroendocrine Tumors | 2 | 2021 | 657 | 0.220 |
Why?
|
Urologic Neoplasms | 2 | 2025 | 314 | 0.220 |
Why?
|
Adrenocortical Carcinoma | 1 | 2024 | 88 | 0.220 |
Why?
|
Sarcoma, Alveolar Soft Part | 1 | 2023 | 44 | 0.220 |
Why?
|
Fibromatosis, Aggressive | 1 | 2024 | 125 | 0.210 |
Why?
|
Receptors, Vascular Endothelial Growth Factor | 2 | 2024 | 662 | 0.210 |
Why?
|
Th1 Cells | 2 | 2019 | 1042 | 0.210 |
Why?
|
Genomics | 4 | 2024 | 5926 | 0.210 |
Why?
|
Urogenital Neoplasms | 1 | 2024 | 130 | 0.210 |
Why?
|
Paraneoplastic Syndromes | 1 | 2024 | 154 | 0.200 |
Why?
|
Antibodies, Blocking | 1 | 2023 | 250 | 0.200 |
Why?
|
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2024 | 230 | 0.200 |
Why?
|
Plant Proteins | 2 | 2023 | 376 | 0.200 |
Why?
|
Occupational Exposure | 1 | 2013 | 1807 | 0.200 |
Why?
|
Female | 54 | 2025 | 397187 | 0.200 |
Why?
|
Neoadjuvant Therapy | 2 | 2025 | 2907 | 0.200 |
Why?
|
Vulvar Neoplasms | 1 | 2025 | 266 | 0.200 |
Why?
|
Adult | 39 | 2025 | 223646 | 0.200 |
Why?
|
Gallbladder Neoplasms | 1 | 2024 | 190 | 0.200 |
Why?
|
Radiation Dosage | 2 | 2020 | 1967 | 0.200 |
Why?
|
Kidney Neoplasms | 3 | 2024 | 4282 | 0.200 |
Why?
|
Male | 48 | 2025 | 364731 | 0.190 |
Why?
|
Sarcoma, Kaposi | 1 | 2024 | 376 | 0.190 |
Why?
|
Bees | 1 | 2021 | 48 | 0.190 |
Why?
|
SEER Program | 2 | 2024 | 1444 | 0.180 |
Why?
|
Thyroid Neoplasms | 1 | 2014 | 2360 | 0.180 |
Why?
|
Carcinoma, Renal Cell | 3 | 2023 | 3187 | 0.180 |
Why?
|
Urinary Bladder Neoplasms | 2 | 2024 | 2195 | 0.180 |
Why?
|
Leukemia, B-Cell | 1 | 2021 | 86 | 0.180 |
Why?
|
Monitoring, Immunologic | 1 | 2021 | 100 | 0.180 |
Why?
|
Uterine Cervical Neoplasms | 2 | 2025 | 2043 | 0.180 |
Why?
|
Watchful Waiting | 1 | 2024 | 492 | 0.170 |
Why?
|
Disease-Free Survival | 7 | 2025 | 6847 | 0.170 |
Why?
|
Consensus | 4 | 2023 | 3211 | 0.170 |
Why?
|
Truth Disclosure | 1 | 2024 | 434 | 0.170 |
Why?
|
Arabidopsis | 1 | 2023 | 466 | 0.170 |
Why?
|
Cancer Vaccines | 2 | 2020 | 1040 | 0.160 |
Why?
|
Recombinant Fusion Proteins | 3 | 2024 | 3740 | 0.160 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2023 | 12252 | 0.160 |
Why?
|
Neoplasm, Residual | 1 | 2024 | 1015 | 0.160 |
Why?
|
Hemangiosarcoma | 1 | 2021 | 215 | 0.160 |
Why?
|
Sezary Syndrome | 1 | 2019 | 80 | 0.160 |
Why?
|
Maryland | 1 | 2019 | 278 | 0.160 |
Why?
|
Receptors, Immunologic | 1 | 2025 | 1418 | 0.150 |
Why?
|
Pyrimidinones | 1 | 2021 | 386 | 0.150 |
Why?
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2023 | 686 | 0.150 |
Why?
|
Protein Kinase Inhibitors | 2 | 2021 | 5704 | 0.150 |
Why?
|
Joints | 1 | 2020 | 324 | 0.150 |
Why?
|
Retrospective Studies | 12 | 2024 | 81760 | 0.150 |
Why?
|
Multiple Organ Failure | 1 | 2020 | 388 | 0.150 |
Why?
|
Receptor, erbB-2 | 2 | 2024 | 2603 | 0.150 |
Why?
|
Mycosis Fungoides | 1 | 2019 | 169 | 0.150 |
Why?
|
Lymphoma, AIDS-Related | 1 | 2018 | 79 | 0.140 |
Why?
|
Kupffer Cells | 1 | 2018 | 143 | 0.140 |
Why?
|
Pyridines | 3 | 2024 | 2894 | 0.140 |
Why?
|
Antibodies, Neutralizing | 3 | 2024 | 2009 | 0.140 |
Why?
|
Neoplastic Syndromes, Hereditary | 1 | 2019 | 249 | 0.140 |
Why?
|
United States | 11 | 2024 | 73039 | 0.140 |
Why?
|
Bile Duct Neoplasms | 1 | 2022 | 614 | 0.140 |
Why?
|
Virus Internalization | 1 | 2020 | 503 | 0.140 |
Why?
|
Granuloma | 1 | 2019 | 329 | 0.130 |
Why?
|
Receptors, Aryl Hydrocarbon | 1 | 2018 | 221 | 0.130 |
Why?
|
Immunity | 2 | 2020 | 1003 | 0.130 |
Why?
|
Neoplasm Invasiveness | 1 | 2024 | 3620 | 0.130 |
Why?
|
Nasopharyngeal Neoplasms | 1 | 2019 | 290 | 0.130 |
Why?
|
Neoplasms, Experimental | 1 | 2021 | 1230 | 0.130 |
Why?
|
Guanine | 2 | 2014 | 280 | 0.130 |
Why?
|
Glutamates | 2 | 2014 | 385 | 0.130 |
Why?
|
Vascular Endothelial Growth Factor A | 3 | 2024 | 3517 | 0.120 |
Why?
|
Oximes | 1 | 2017 | 303 | 0.120 |
Why?
|
Matrix Metalloproteinases | 1 | 2018 | 393 | 0.120 |
Why?
|
Deoxycytidine | 3 | 2025 | 887 | 0.120 |
Why?
|
Lymphoma, B-Cell | 1 | 2022 | 945 | 0.120 |
Why?
|
Small Cell Lung Carcinoma | 1 | 2020 | 454 | 0.120 |
Why?
|
Natural Language Processing | 1 | 2024 | 1203 | 0.120 |
Why?
|
Immunoconjugates | 2 | 2024 | 975 | 0.120 |
Why?
|
Diarrhea | 1 | 2021 | 1320 | 0.120 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 1 | 2025 | 1437 | 0.120 |
Why?
|
Prospective Studies | 12 | 2025 | 54924 | 0.120 |
Why?
|
Hematopoietic Stem Cell Transplantation | 2 | 2024 | 5717 | 0.120 |
Why?
|
Recurrence | 6 | 2024 | 8509 | 0.110 |
Why?
|
Antigens, CD | 1 | 2025 | 4035 | 0.110 |
Why?
|
Pancreatic Neoplasms | 1 | 2012 | 5442 | 0.110 |
Why?
|
Drug Evaluation, Preclinical | 2 | 2017 | 1339 | 0.110 |
Why?
|
Fatal Outcome | 1 | 2019 | 1836 | 0.110 |
Why?
|
Congresses as Topic | 1 | 2019 | 812 | 0.110 |
Why?
|
Treatment Outcome | 14 | 2025 | 65379 | 0.110 |
Why?
|
Myelodysplastic Syndromes | 1 | 2023 | 1399 | 0.110 |
Why?
|
Kaplan-Meier Estimate | 5 | 2024 | 6525 | 0.110 |
Why?
|
Animals | 12 | 2024 | 169285 | 0.110 |
Why?
|
Immunomodulation | 1 | 2017 | 549 | 0.110 |
Why?
|
Medical Records | 1 | 2018 | 1410 | 0.100 |
Why?
|
Colitis | 1 | 2021 | 1242 | 0.100 |
Why?
|
Herpesvirus 4, Human | 1 | 2018 | 1082 | 0.100 |
Why?
|
Antibodies, Viral | 1 | 2024 | 3214 | 0.100 |
Why?
|
Clinical Trials, Phase I as Topic | 1 | 2014 | 330 | 0.100 |
Why?
|
Virus Replication | 1 | 2020 | 2458 | 0.100 |
Why?
|
Pharmaceutical Preparations | 1 | 2020 | 1088 | 0.100 |
Why?
|
T-Lymphocytes, Helper-Inducer | 1 | 2018 | 977 | 0.100 |
Why?
|
Epstein-Barr Virus Infections | 1 | 2018 | 617 | 0.100 |
Why?
|
Oncolytic Virotherapy | 1 | 2018 | 520 | 0.100 |
Why?
|
Program Evaluation | 1 | 2020 | 2507 | 0.100 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2023 | 1642 | 0.100 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2021 | 2433 | 0.100 |
Why?
|
Pentostatin | 1 | 2011 | 26 | 0.100 |
Why?
|
Insulin-Like Growth Factor II | 1 | 2013 | 271 | 0.100 |
Why?
|
Immunotoxins | 1 | 2012 | 175 | 0.090 |
Why?
|
Leukocytes, Mononuclear | 3 | 2024 | 1854 | 0.090 |
Why?
|
Imidazoles | 1 | 2017 | 1169 | 0.090 |
Why?
|
Societies, Medical | 1 | 2023 | 3968 | 0.090 |
Why?
|
Pregnancy Outcome | 1 | 2021 | 2972 | 0.090 |
Why?
|
Pyrazoles | 1 | 2021 | 2028 | 0.090 |
Why?
|
Perception | 1 | 2017 | 1209 | 0.090 |
Why?
|
Enzyme Inhibitors | 1 | 2021 | 3728 | 0.090 |
Why?
|
Colorectal Neoplasms | 2 | 2021 | 6975 | 0.090 |
Why?
|
Sarcoma | 1 | 2021 | 1806 | 0.090 |
Why?
|
Dendritic Cells | 2 | 2020 | 2747 | 0.090 |
Why?
|
Phylogeny | 3 | 2024 | 2843 | 0.090 |
Why?
|
Neoplasm Metastasis | 4 | 2022 | 4913 | 0.090 |
Why?
|
Radiotherapy Dosage | 3 | 2022 | 2916 | 0.080 |
Why?
|
T-Lymphocyte Subsets | 1 | 2018 | 1816 | 0.080 |
Why?
|
Cell Cycle Proteins | 1 | 2021 | 3445 | 0.080 |
Why?
|
Evidence-Based Medicine | 1 | 2021 | 3706 | 0.080 |
Why?
|
Remission Induction | 3 | 2024 | 2410 | 0.080 |
Why?
|
Artificial Intelligence | 1 | 2024 | 2666 | 0.080 |
Why?
|
Signal Transduction | 3 | 2018 | 23648 | 0.080 |
Why?
|
Communication | 1 | 2023 | 3905 | 0.080 |
Why?
|
Electronic Health Records | 2 | 2024 | 4887 | 0.080 |
Why?
|
Indoles | 1 | 2017 | 1836 | 0.080 |
Why?
|
Prednisone | 2 | 2024 | 1567 | 0.080 |
Why?
|
Head and Neck Neoplasms | 1 | 2023 | 2931 | 0.080 |
Why?
|
Immune Tolerance | 1 | 2018 | 2323 | 0.080 |
Why?
|
Kidney Transplantation | 1 | 2024 | 4262 | 0.080 |
Why?
|
Killer Cells, Natural | 1 | 2018 | 2211 | 0.080 |
Why?
|
Young Adult | 7 | 2024 | 60066 | 0.070 |
Why?
|
Leukemia, Myeloid, Acute | 1 | 2023 | 3626 | 0.070 |
Why?
|
Ovarian Neoplasms | 1 | 2024 | 4916 | 0.070 |
Why?
|
Mycobacterium tuberculosis | 1 | 2019 | 1930 | 0.070 |
Why?
|
CD4 Lymphocyte Count | 2 | 2024 | 2596 | 0.070 |
Why?
|
Liver | 1 | 2023 | 7578 | 0.070 |
Why?
|
Sulfonamides | 1 | 2017 | 1982 | 0.070 |
Why?
|
Adjuvants, Immunologic | 2 | 2023 | 999 | 0.070 |
Why?
|
Peritoneal Neoplasms | 1 | 2013 | 714 | 0.070 |
Why?
|
Drug Administration Schedule | 3 | 2021 | 4861 | 0.070 |
Why?
|
Autoimmune Diseases | 1 | 2019 | 2257 | 0.070 |
Why?
|
Drug Combinations | 1 | 2013 | 2089 | 0.070 |
Why?
|
B-Lymphocytes | 2 | 2018 | 4793 | 0.070 |
Why?
|
Health Services Accessibility | 1 | 2024 | 5520 | 0.070 |
Why?
|
Software | 1 | 2020 | 4480 | 0.070 |
Why?
|
Breast Neoplasms | 2 | 2024 | 21207 | 0.060 |
Why?
|
Insulin-Like Growth Factor I | 1 | 2013 | 1942 | 0.060 |
Why?
|
Cyclophosphamide | 1 | 2011 | 2227 | 0.060 |
Why?
|
Chemotherapy, Adjuvant | 2 | 2024 | 3556 | 0.060 |
Why?
|
Fluorouracil | 1 | 2010 | 1652 | 0.060 |
Why?
|
Inflammatory Bowel Diseases | 1 | 2019 | 2442 | 0.060 |
Why?
|
1-Acylglycerophosphocholine O-Acyltransferase | 1 | 2024 | 9 | 0.060 |
Why?
|
Arthritis, Rheumatoid | 1 | 2020 | 3781 | 0.060 |
Why?
|
T-Lymphocytes, Regulatory | 1 | 2018 | 3115 | 0.060 |
Why?
|
Maytansine | 1 | 2024 | 88 | 0.060 |
Why?
|
Phytochrome A | 1 | 2023 | 2 | 0.060 |
Why?
|
Histone Deacetylase Inhibitors | 2 | 2023 | 778 | 0.050 |
Why?
|
Disease Progression | 4 | 2023 | 13668 | 0.050 |
Why?
|
Prognosis | 4 | 2020 | 30009 | 0.050 |
Why?
|
Intention to Treat Analysis | 1 | 2024 | 416 | 0.050 |
Why?
|
Pregnancy | 2 | 2024 | 30255 | 0.050 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3115 | 0.050 |
Why?
|
Adrenal Cortex Neoplasms | 1 | 2024 | 161 | 0.050 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3238 | 0.050 |
Why?
|
Chemokine CCL5 | 1 | 2022 | 214 | 0.050 |
Why?
|
Interleukin-5 | 1 | 2022 | 267 | 0.050 |
Why?
|
Philadelphia Chromosome | 1 | 2022 | 119 | 0.050 |
Why?
|
Proto-Oncogene Proteins c-sis | 1 | 2022 | 254 | 0.050 |
Why?
|
Quality of Life | 1 | 2023 | 13490 | 0.050 |
Why?
|
Early Termination of Clinical Trials | 1 | 2021 | 70 | 0.050 |
Why?
|
Vaccination | 2 | 2024 | 3437 | 0.050 |
Why?
|
Survival Rate | 3 | 2020 | 12840 | 0.040 |
Why?
|
Follow-Up Studies | 3 | 2020 | 39354 | 0.040 |
Why?
|
Gene Expression Regulation | 1 | 2018 | 11930 | 0.040 |
Why?
|
Azetidines | 1 | 2021 | 152 | 0.040 |
Why?
|
Volatile Organic Compounds | 1 | 2021 | 86 | 0.040 |
Why?
|
Tacrolimus | 1 | 2024 | 750 | 0.040 |
Why?
|
Maximum Tolerated Dose | 2 | 2014 | 899 | 0.040 |
Why?
|
Membrane Glycoproteins | 1 | 2010 | 3713 | 0.040 |
Why?
|
Mitogen-Activated Protein Kinase Kinases | 1 | 2022 | 637 | 0.040 |
Why?
|
Drug Therapy, Combination | 2 | 2020 | 6316 | 0.040 |
Why?
|
Polyethylene Glycols | 1 | 2025 | 1197 | 0.040 |
Why?
|
Survival Analysis | 2 | 2024 | 10099 | 0.040 |
Why?
|
Organ Culture Techniques | 1 | 2021 | 796 | 0.040 |
Why?
|
Drug Repositioning | 1 | 2021 | 246 | 0.040 |
Why?
|
Dose-Response Relationship, Radiation | 1 | 2020 | 876 | 0.040 |
Why?
|
Brain Neoplasms | 1 | 2019 | 9118 | 0.040 |
Why?
|
Tumor Burden | 1 | 2024 | 1906 | 0.040 |
Why?
|
Creatinine | 1 | 2024 | 1918 | 0.040 |
Why?
|
Interleukin-2 | 1 | 2025 | 1895 | 0.040 |
Why?
|
Africa South of the Sahara | 1 | 2020 | 752 | 0.040 |
Why?
|
Adolescent | 5 | 2024 | 89169 | 0.040 |
Why?
|
fms-Like Tyrosine Kinase 3 | 1 | 2020 | 494 | 0.030 |
Why?
|
Mammals | 1 | 2022 | 1135 | 0.030 |
Why?
|
Cisplatin | 2 | 2014 | 1660 | 0.030 |
Why?
|
Doxorubicin | 1 | 2023 | 2234 | 0.030 |
Why?
|
Cytokines | 2 | 2022 | 7452 | 0.030 |
Why?
|
Dogs | 1 | 2021 | 3845 | 0.030 |
Why?
|
Drug Interactions | 1 | 2020 | 1419 | 0.030 |
Why?
|
Receptors, Antigen, T-Cell | 1 | 2025 | 2568 | 0.030 |
Why?
|
Methotrexate | 1 | 2022 | 1721 | 0.030 |
Why?
|
Data Collection | 1 | 2024 | 3326 | 0.030 |
Why?
|
Early Diagnosis | 1 | 2020 | 1194 | 0.030 |
Why?
|
Infusions, Intravenous | 1 | 2019 | 2230 | 0.030 |
Why?
|
Databases, Factual | 2 | 2021 | 8080 | 0.030 |
Why?
|
Lymphocytes | 1 | 2022 | 2614 | 0.030 |
Why?
|
ADP Ribose Transferases | 1 | 2014 | 90 | 0.030 |
Why?
|
Immunotherapy, Adoptive | 1 | 2024 | 1512 | 0.030 |
Why?
|
Exotoxins | 1 | 2014 | 123 | 0.030 |
Why?
|
Risk Factors | 3 | 2017 | 74944 | 0.030 |
Why?
|
Case-Control Studies | 1 | 2012 | 22290 | 0.030 |
Why?
|
Hypothyroidism | 1 | 2019 | 667 | 0.030 |
Why?
|
Mice | 4 | 2024 | 82049 | 0.030 |
Why?
|
Evolution, Molecular | 1 | 2021 | 1896 | 0.030 |
Why?
|
Piperidines | 1 | 2021 | 1667 | 0.030 |
Why?
|
Neoplasm Recurrence, Local | 2 | 2023 | 9419 | 0.030 |
Why?
|
Immunologic Factors | 1 | 2022 | 1596 | 0.030 |
Why?
|
Body Weight | 1 | 2023 | 4627 | 0.030 |
Why?
|
Blood Cell Count | 1 | 2013 | 406 | 0.030 |
Why?
|
Lymphocyte Subsets | 1 | 2013 | 313 | 0.030 |
Why?
|
Immunoglobulin G | 1 | 2024 | 4568 | 0.030 |
Why?
|
DNA Repair | 1 | 2021 | 2050 | 0.020 |
Why?
|
Genome | 1 | 2020 | 1754 | 0.020 |
Why?
|
Host-Pathogen Interactions | 1 | 2020 | 1469 | 0.020 |
Why?
|
CA-125 Antigen | 1 | 2014 | 281 | 0.020 |
Why?
|
Sex Distribution | 1 | 2017 | 2278 | 0.020 |
Why?
|
Folic Acid Antagonists | 1 | 2011 | 74 | 0.020 |
Why?
|
Hypersensitivity | 1 | 2020 | 1172 | 0.020 |
Why?
|
Age Distribution | 1 | 2017 | 2873 | 0.020 |
Why?
|
Virulence Factors | 1 | 2014 | 502 | 0.020 |
Why?
|
Sequence Analysis, DNA | 1 | 2021 | 4786 | 0.020 |
Why?
|
Health Care Surveys | 1 | 2017 | 2434 | 0.020 |
Why?
|
Child | 3 | 2023 | 80917 | 0.020 |
Why?
|
Infant | 2 | 2023 | 36535 | 0.020 |
Why?
|
Vinblastine | 1 | 2011 | 487 | 0.020 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2022 | 4415 | 0.020 |
Why?
|
Antiviral Agents | 1 | 2022 | 3072 | 0.020 |
Why?
|
Child, Preschool | 2 | 2023 | 42669 | 0.020 |
Why?
|
Lymphocyte Count | 1 | 2011 | 794 | 0.020 |
Why?
|
Bacterial Toxins | 1 | 2014 | 922 | 0.020 |
Why?
|
Risk | 1 | 2020 | 9613 | 0.020 |
Why?
|
Hydroxamic Acids | 1 | 2011 | 483 | 0.020 |
Why?
|
Drug Therapy | 1 | 2011 | 504 | 0.020 |
Why?
|
Cohort Studies | 2 | 2021 | 41753 | 0.020 |
Why?
|
Pneumonia | 1 | 2019 | 2163 | 0.020 |
Why?
|
Registries | 1 | 2023 | 8375 | 0.020 |
Why?
|
Cause of Death | 1 | 2017 | 3721 | 0.020 |
Why?
|
Myeloid Cells | 1 | 2011 | 839 | 0.020 |
Why?
|
Medicare | 1 | 2024 | 6809 | 0.020 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2023 | 9016 | 0.020 |
Why?
|
Phenotype | 1 | 2024 | 16726 | 0.020 |
Why?
|
Proteins | 1 | 2020 | 6009 | 0.020 |
Why?
|
Pain | 1 | 2020 | 5099 | 0.020 |
Why?
|
Gene Expression Profiling | 1 | 2021 | 9540 | 0.010 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2019 | 5341 | 0.010 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2011 | 3814 | 0.010 |
Why?
|
Membrane Proteins | 1 | 2020 | 7876 | 0.010 |
Why?
|
Socioeconomic Factors | 1 | 2017 | 7852 | 0.010 |
Why?
|
Smoking | 1 | 2020 | 9092 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2023 | 26421 | 0.010 |
Why?
|
Comorbidity | 1 | 2017 | 10590 | 0.010 |
Why?
|
Radiography | 1 | 2013 | 6986 | 0.010 |
Why?
|
Aging | 1 | 2021 | 8743 | 0.010 |
Why?
|
Mice, Inbred BALB C | 1 | 2011 | 6231 | 0.010 |
Why?
|
Risk Assessment | 1 | 2022 | 24318 | 0.010 |
Why?
|
Prevalence | 1 | 2017 | 15869 | 0.010 |
Why?
|
Time Factors | 1 | 2021 | 40220 | 0.010 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2010 | 10763 | 0.010 |
Why?
|
Bacterial Proteins | 1 | 2011 | 3840 | 0.010 |
Why?
|
T-Lymphocytes | 1 | 2011 | 10266 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 1 | 2020 | 36741 | 0.010 |
Why?
|